Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40 According to Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned an average recommendation of “Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $63.40.

A number of research firms have issued reports on MAZE. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Maze Therapeutics in a report on Thursday, September 24th. Citigroup started coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple EPS forecasts. The firm improved its estimates for Q3 2026 to a loss of $0.70 per share from $0.77, Q4 2026 to a loss of $0.71 from $0.80, FY2026 to a loss of $2.63 from $2.81, FY2027 to a loss of $2.60 from $3.27, FY2028 to a loss of $2.23 from $2.89, and FY2029 to a loss of $2.05 from $2.46. Although Maze is still expected to report losses, the revisions suggest expectations for narrower losses and may support investor sentiment. MAZE Stock Gets Increased EPS Forecast from HC Wainwright
• Positive Sentiment: The analyst maintained a Buy rating and $110 price target. HC Wainwright’s target implies substantial upside relative to Maze’s recent trading level, reflecting confidence in the company’s pipeline and longer-term commercial potential. Maze Therapeutics analyst coverage
• Neutral Sentiment: Maze will present clinical and preclinical kidney-disease data at ASN Kidney Week. An oral presentation will feature previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, while posters will discuss preclinical work supporting MZE782 and SLC6A19 inhibition. The October 21–25 event could provide additional visibility into the programs, though the announcement did not include new efficacy results. Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
• Negative Sentiment: HC Wainwright sharply reduced its FY2030 EPS forecast to a loss of $2.16 per share from a loss of $0.72. The downgrade contrasts with the nearer-term improvements and highlights uncertainty around Maze’s long-term path to profitability. The consensus forecast remains a loss of $2.72 per share for the current year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider directly owned 26,250 shares of the company’s stock, valued at $723,975. The trade was a 22.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares of the company’s stock, valued at approximately $477,189.79. This represents a 65.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 192,991 shares of company stock worth $5,152,084. 5.30% of the stock is owned by insiders.

Institutional Trading of Maze Therapeutics

Large investors have recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $48,000. Royal Bank of Canada lifted its position in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $80,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Maze Therapeutics during the 4th quarter worth approximately $145,000. Finally, Persistent Asset Partners Ltd bought a new stake in Maze Therapeutics in the 2nd quarter valued at $200,000.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $26.25 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics has a 52 week low of $21.95 and a 52 week high of $53.65. The company’s 50 day moving average price is $26.88 and its two-hundred day moving average price is $27.57. The company has a market capitalization of $1.46 billion, a P/E ratio of -10.42 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). On average, analysts expect that Maze Therapeutics will post -2.7 earnings per share for the current fiscal year.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.